CD86 and lymphoma: Consistent with no PU.1 induction detectable upon ADR treatment of senescence-incapable Suv39h1-deficient lymphoma cells (see above), MHC I and II, CD86 and PD-L1 expression levels remained largely unchanged or were much less induced compared to Suv39h1-proficient cells (Supplementary Fig. 9b).